Literature DB >> 7693357

Galanin--a neuroendocrine peptide.

T Bartfai1, T Hökfelt, U Langel.   

Abstract

Galanin is a widely distributed 29/30 amino acid long neuropeptide with multiple biological effects. It inhibits glucose-induced insulin release, hippocampal acetylcholine release, hippocampal glutamate but not GABA release, and it lowers spinal excitability and firing of locus coeruleus neurons. It stimulates food (fat) intake and growth hormone release upon hypothalamic or i.c.v. injection. Galanin actions are mediated via high affinity Gi/G0 protein-coupled receptors--involving effector systems such as K(+)-, Ca(2+)-channels and adenylate cyclase. Galanin receptor agonists are thought to have therapeutic application in treatment of chronic pain and prevention of ischemic damage; galanin receptor antagonists have therapeutic potential in the treatment of Alzheimer's disease, depression, and feeding disorders.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693357

Source DB:  PubMed          Journal:  Crit Rev Neurobiol        ISSN: 0892-0915


  29 in total

1.  Modulation of hippocampal excitability and seizures by galanin.

Authors:  A M Mazarati; J G Hohmann; A Bacon; H Liu; R Sankar; R A Steiner; D Wynick; C G Wasterlain
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

2.  Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests.

Authors:  Tamas Bartfai; Xiaoying Lu; Hedieh Badie-Mahdavi; Alasdair M Barr; Andrey Mazarati; Xiao-Ying Hua; Tony Yaksh; Gebhard Haberhauer; Susana Conde Ceide; Laurent Trembleau; Laszlo Somogyi; Lenz Kröck; Julius Rebek
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-06       Impact factor: 11.205

3.  The role of the neuropeptide galanin in forming type-specific behavioral characteristics.

Authors:  V I Lyudyno; I N Abdurasulova; V M Klimenko
Journal:  Neurosci Behav Physiol       Date:  2008-01

Review 4.  Galanin: a potential role in mesolimbic dopamine-mediated instrumental behavior.

Authors:  John K Robinson; Ariel Brewer
Journal:  Neurosci Biobehav Rev       Date:  2008-06-03       Impact factor: 8.989

5.  Synthesis and biological evaluation of novel pyrimidine derivatives as sub-micromolar affinity ligands of GalR2.

Authors:  Vasudeva Naidu Sagi; Tianyu Liu; Xiaoying Lu; Tamas Bartfai; Edward Roberts
Journal:  Bioorg Med Chem Lett       Date:  2011-09-25       Impact factor: 2.823

6.  Targeted disruption of the galanin gene attenuates inflammatory responses in murine skin.

Authors:  Sabine M Schmidhuber; Anna Starr; David Wynick; Barbara Kofler; Susan D Brain
Journal:  J Mol Neurosci       Date:  2007-11-13       Impact factor: 3.444

7.  Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus.

Authors:  A M Mazarati; H Liu; U Soomets; R Sankar; D Shin; H Katsumori; U Langel; C G Wasterlain
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

8.  Deficits in trace cued fear conditioning in galanin-treated rats and galanin-overexpressing transgenic mice.

Authors:  Jefferson W Kinney; Grzegorz Starosta; Andrew Holmes; Craige C Wrenn; Rebecca J Yang; Ashley P Harris; Katharine C Long; Jacqueline N Crawley
Journal:  Learn Mem       Date:  2002 Jul-Aug       Impact factor: 2.460

9.  New high affinity peptide antagonists to the spinal galanin receptor.

Authors:  X J Xu; Z Wiesenfeld-Hallin; U Langel; K Bedecs; T Bartfai
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

10.  Galanin and galanin receptor expression in neuroblastic tumours: correlation with their differentiation status.

Authors:  Y Perel; L Amrein; E Dobremez; J Rivel; J Y Daniel; M Landry
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.